enGene Therapeutics Inc. Q3 2026: Net loss $30.2M, EPS ($0.43) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.enGene Therapeutics reported a Q3 2026 net loss of $30.2M ($0.43 EPS), widening from the prior year's $25.8M. The company cut its workforce by ~50% to conserve cash for LEGEND study completion and BLA planning. Interim LEGEND results showed a 54% complete response rate, prompting the addition of a surfactant cohort. enGene is advancing CMC and pre-commercial activities toward a potential 2027 launch.
enGene Therapeutics Inc. reported a net loss of $30.2M for the quarter ended April 30, 2026, compared with a net loss of $25.8M in the year-ago quarter; diluted loss per share was $0.43 versus $0.51 in the prior-year quarter.
Financial Highlights
- Net income: Net loss of $30.2M for the quarter ended Apr 30, 2026, vs. net loss of $25.8M in the year-ago quarter — increased loss of $4.4M YoY.
- Diluted EPS: Net loss per share (basic & diluted) $0.43 for the quarter ended Apr 30, 2026, vs. $0.51 in the year-ago quarter (down $0.08 YoY).
Business Highlights
- Clinical milestone: Interim results from the LEGEND pivotal cohort showed a 54.0% any-time complete response (CR) rate and Kaplan-Meier–estimated durability at 6–12 months, supporting BLA planning.
- Program expansion: Company added a surfactant (polidocanol) cohort to the LEGEND study to potentially improve bladder delivery; enrollment has begun for up to ~80 patients.
- Strategic restructuring: enGene implemented an approximately 50% workforce reduction to conserve cash while retaining resources to complete LEGEND Cohort 1, enroll the surfactant cohort, and pursue BLA activities.
- Operational readiness: Advanced CMC, clinical operations, and pre-commercial activities, including process validation, to support planned BLA initiation and a potential 2027 launch.
Original SEC Filing: enGene Therapeutics Inc. [ ENGN ] - 10-Q - Jun. 15, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.